(Total Views: 184)
Posted On: 12/22/2022 3:01:24 PM
Post# of 25428
$NRBO Upcoming Catalyst per 10Q any day
*** Upcoming Catalyst, Phase 2 clinical trial of ANA001 for treatment of moderate COVID-19
analysis of the clinical trial data, which is expected in the fourth quarter of 2022.
https://www.sec.gov/ix?doc=/Archives/edgar/da...30x10q.htm
*** New insider Goldman Sachs 1.2M
https://www.sec.gov/Archives/edgar/data/16382...2/doc3.xml
*** Completed RS
https://finance.yahoo.com/news/neurobo-pharma...00951.html
*** Completed Offering $3
https://finance.yahoo.com/news/neurobo-announ...00773.html
*** Low Float, Price near bottom.
*** Short Interest ~14%, Cost to Borrow 235%
*** Upcoming Catalyst, Phase 2 clinical trial of ANA001 for treatment of moderate COVID-19
analysis of the clinical trial data, which is expected in the fourth quarter of 2022.
https://www.sec.gov/ix?doc=/Archives/edgar/da...30x10q.htm
*** New insider Goldman Sachs 1.2M
https://www.sec.gov/Archives/edgar/data/16382...2/doc3.xml
*** Completed RS
https://finance.yahoo.com/news/neurobo-pharma...00951.html
*** Completed Offering $3
https://finance.yahoo.com/news/neurobo-announ...00773.html
*** Low Float, Price near bottom.
*** Short Interest ~14%, Cost to Borrow 235%
(0)
(0)
